<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01490073</url>
  </required_header>
  <id_info>
    <org_study_id>7928</org_study_id>
    <nct_id>NCT01490073</nct_id>
  </id_info>
  <brief_title>The Effect of Nitroglycerin on the Intrauterine Device (IUD) Insertion Experience in Nulliparous Women</brief_title>
  <official_title>The Effect of Nitroglycerin on the IUD Insertion Experience in Nulliparous Women: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American College of Obstetricians and Gynecologists</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Increasing ease of access of long-acting birth control methods, like intrauterine devices
      (IUDs), is an important way to reduce the risk of unintended pregnancy. Unfortunately, fear
      of IUD insertion in women who have not had children is common among health care providers and
      women alike, and this limits IUD use. To increase acceptance of this highly effective birth
      control method, there is a need to explore new, low cost, and easily applied methods to
      improve the insertion experience. This is a pilot study to evaluate the effectiveness and
      acceptability of nitroglycerin ointment applied vaginally to improve the IUD insertion
      experience for both patient and provider. The investigators hypothesis is that nitroglycerin
      ointment will decrease the pain associated with IUD insertion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Increasing acceptability and use of long acting reversible contraceptive methods like the
      intrauterine device (IUD) is an important strategy to reduce the risk of unintended
      pregnancy. Unfortunately, fear of IUD insertion in nulliparous women is common among health
      care providers and women alike, and this limits IUD use. While many health care providers
      assume that placement is more difficult in nulliparous women, there is no evidence that the
      risk of unsuccessful insertion is higher. Women worry about pain with insertion, and their
      fear is not unfounded as U.S. and international data have shown that nulliparous women report
      approximately twice as much pain with IUD insertion compared to parous women.

      A key difference between nulliparous and multiparous women is the resistance of the cervix.
      While cervical dilation is uncommonly needed during IUD placement, force is often required to
      pass the insertion device through the internal os. Although misoprostol and ibuprofen have
      been studied as ways to improve the IUD insertion experience, neither has proved effective,
      and misoprostol actually has been shown to increase pain. Therefore, to increase acceptance
      of this highly effective contraceptive, there is a need to investigate novel, low cost,
      easily applied and accessible techniques to improve the insertion experience.

      Nitric oxide (NO) donors, including nitroglycerin, nitroprusside, isosorbide mononitrate and
      isosorbide dinitrate, have effects on the animal and human cervix. Both nitroglycerin and
      isosorbide mononitrate tablets administered vaginally have been shown in RCTs to induce
      effective cervical ripening with minimal side effects for first trimester abortion compared
      to placebo. Nitroprusside and isosorbide dinitrate gel given intracervically prior to first
      trimester abortion also have showed minimal side effects in several RCTs, but with mixed
      results regarding effectiveness. Additional safety data about NO donors applied topically to
      skin and mucosal surfaces is well established through the routine use of topical
      nitroglycerin for treatment of anal fissures.

      Although a recent randomized controlled trial (RCT) comparing nitroprusside gel to
      misoprostol for cervical ripening prior to first trimester surgical abortion found superior
      cervical dilation in the misoprostol group, there was no significant difference in cervical
      dilation up to 5 mm. While most studies of abortion are concerned with providing adequate
      dilation beyond 8 mm, the cervical remodeling that is necessary to help with IUD insertion is
      much less, as the levonorgestrel intrauterine system (LNG-IUS) inserter is only 4.75 mm in
      diameter. Since NO donors are smooth muscle relaxants, they are expected to induce cervical
      ripening without causing uterine cramping, which is the most significant side effect of
      misoprostol.

      Nitroglycerin is inexpensive, stable at room temperature, and readily available in tablet and
      ointment form, as well as in a dextrose solution for intravenous administration. The ointment
      form is commonly applied topically for the treatment of anal fissures. We propose the
      following aims:

        1. To determine if nitroglycerin ointment applied vaginally 30-45 minutes prior to IUD
           insertion improves pain among nulliparous women compared to a placebo ointment.
           Self-reported pain scores on a 100 mm VAS will be assessed at multiple time points
           during and after the IUD insertion procedure. In addition, overall satisfaction and
           adverse effects will be evaluated.

        2. To determine if nitroglycerin ointment applied vaginally 30-45 minutes prior to IUD
           insertion improves ease of IUD insertion for the provider compared to a placebo
           ointment. In addition, need for additional dilation, additional pain medicine such as
           paracervical block, inability to place the IUD, and complications will be tracked.

        3. To determine if nitroglycerin ointment applied vaginally 30-45 minutes prior to IUD
           insertion is safe and well tolerated. Side effects related to treatment with
           nitroglycerin ointment or placebo will be compared. Blood pressure will be measured at
           multiple time points.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2012</start_date>
  <completion_date type="Actual">November 1, 2012</completion_date>
  <primary_completion_date type="Actual">November 1, 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient-reported Pain at Passage of Insertion Device Through Cervix, as Measured on a 100 mm VAS</measure>
    <time_frame>30-45 minutes after insertion of nitroglycerin ointment</time_frame>
    <description>Patient-reported pain at passage of insertion device through cervix, as measured on a 100 mm VAS. VAS anchors: 0 indicates no pain, and 100 indicates worst pain imaginable.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Provider Ease With Intrauterine Device Insertion Measured on a 100 mm VAS</measure>
    <time_frame>30-45 minutes after insertion of nitroglycerin ointment</time_frame>
    <description>Provider ease with intrauterine device insertion measured on a 100 mm VAS. VAS (visual analog scale) anchors: 0 indicates easiest insertion imaginable, 100 indicates most difficult insertion imaginable</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Contraception</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Active nitroglycerin ointment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo ointment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insertion of nitroglycerin ointment</intervention_name>
    <description>Nitroglycerin ointment inserted into the vagina 30-45 minutes prior to IUD insertion</description>
    <arm_group_label>Active nitroglycerin ointment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insertion of placebo ointment</intervention_name>
    <description>Placebo ointment inserted into the vagina 30-45 minutes prior to IUD insertion</description>
    <arm_group_label>Placebo ointment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. age 18-45 years,

          2. generally healthy,

          3. requesting a LNG-IUS for contraception as the primary indication

        Exclusion Criteria:

          1. Previous pregnancy beyond 20 weeks;

          2. previous IUD placement or attempted IUD placement;

          3. previous cervical cold knife cone (CKC) or loop electrosurgical excision procedure
             (LEEP);

          4. contraindication to LNG-IUS (including pregnancy, fibroids that distort the uterine
             cavity, exam consistent with PID, allergy to any component of the LNG-IUS, etc);

          5. concurrent use of any form of nitrate therapy or medications that interact with
             nitroglycerin (such as phosphodiesterase V inhibitors);

          6. known allergy to nitroglycerine or common topical ointment ingredients;

          7. known renal or hepatic impairment;

          8. history of hypertensive or hypotensive disorder;

          9. history of migraine, cluster headaches, or vascular headaches;

         10. history of myocardial infarction;

         11. uncontrolled congestive heart failure;

         12. unstable angina;

         13. tobacco or alcohol amblyopia;

         14. congenital optic atrophy;

         15. blood pressure less than 90/55 or greater than 150/100 in office prior to speculum
             exam
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Planned Parenthood Columbia Willamette</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>December 8, 2011</study_first_submitted>
  <study_first_submitted_qc>December 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2011</study_first_posted>
  <results_first_submitted>February 28, 2019</results_first_submitted>
  <results_first_submitted_qc>April 3, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 26, 2019</results_first_posted>
  <last_update_submitted>April 3, 2019</last_update_submitted>
  <last_update_submitted_qc>April 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Elizabeth Micks</investigator_full_name>
    <investigator_title>Instructor and Fellow in Family Planning, Department of Obstetrics and Gynecology</investigator_title>
  </responsible_party>
  <keyword>Intrauterine device</keyword>
  <keyword>Pain</keyword>
  <keyword>Contraception</keyword>
  <keyword>Nitroglycerin</keyword>
  <keyword>Nitric oxide donor</keyword>
  <keyword>Intrauterine device insertion</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitroglycerin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Active Nitroglycerin Ointment</title>
          <description>Insertion of nitroglycerin ointment: Nitroglycerin ointment inserted into the vagina 30-45 minutes prior to IUD insertion</description>
        </group>
        <group group_id="P2">
          <title>Placebo Ointment</title>
          <description>Insertion of placebo ointment: Placebo ointment inserted into the vagina 30-45 minutes prior to IUD insertion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active Nitroglycerin Ointment</title>
          <description>Insertion of nitroglycerin ointment: Nitroglycerin ointment inserted into the vagina 30-45 minutes prior to IUD insertion</description>
        </group>
        <group group_id="B2">
          <title>Placebo Ointment</title>
          <description>Insertion of placebo ointment: Placebo ointment inserted into the vagina 30-45 minutes prior to IUD insertion</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.3" spread="6.9"/>
                    <measurement group_id="B2" value="25.7" spread="4.4"/>
                    <measurement group_id="B3" value="27.04" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current smoker</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patient-reported Pain at Passage of Insertion Device Through Cervix, as Measured on a 100 mm VAS</title>
        <description>Patient-reported pain at passage of insertion device through cervix, as measured on a 100 mm VAS. VAS anchors: 0 indicates no pain, and 100 indicates worst pain imaginable.</description>
        <time_frame>30-45 minutes after insertion of nitroglycerin ointment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Nitroglycerin Ointment</title>
            <description>Insertion of nitroglycerin ointment: Nitroglycerin ointment inserted into the vagina 30-45 minutes prior to IUD insertion</description>
          </group>
          <group group_id="O2">
            <title>Placebo Ointment</title>
            <description>Insertion of placebo ointment: Placebo ointment inserted into the vagina 30-45 minutes prior to IUD insertion</description>
          </group>
        </group_list>
        <measure>
          <title>Patient-reported Pain at Passage of Insertion Device Through Cervix, as Measured on a 100 mm VAS</title>
          <description>Patient-reported pain at passage of insertion device through cervix, as measured on a 100 mm VAS. VAS anchors: 0 indicates no pain, and 100 indicates worst pain imaginable.</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.8" spread="25.2"/>
                    <measurement group_id="O2" value="53.9" spread="28.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Provider Ease With Intrauterine Device Insertion Measured on a 100 mm VAS</title>
        <description>Provider ease with intrauterine device insertion measured on a 100 mm VAS. VAS (visual analog scale) anchors: 0 indicates easiest insertion imaginable, 100 indicates most difficult insertion imaginable</description>
        <time_frame>30-45 minutes after insertion of nitroglycerin ointment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Nitroglycerin Ointment</title>
            <description>Insertion of nitroglycerin ointment: Nitroglycerin ointment inserted into the vagina 30-45 minutes prior to IUD insertion</description>
          </group>
          <group group_id="O2">
            <title>Placebo Ointment</title>
            <description>Insertion of placebo ointment: Placebo ointment inserted into the vagina 30-45 minutes prior to IUD insertion</description>
          </group>
        </group_list>
        <measure>
          <title>Provider Ease With Intrauterine Device Insertion Measured on a 100 mm VAS</title>
          <description>Provider ease with intrauterine device insertion measured on a 100 mm VAS. VAS (visual analog scale) anchors: 0 indicates easiest insertion imaginable, 100 indicates most difficult insertion imaginable</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.4" spread="23.8"/>
                    <measurement group_id="O2" value="22.8" spread="29.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 days</time_frame>
      <desc>Subjects were asked about the presence of side effects including headache, lightheadedness, palpitations, nausea, vomiting, cramping and diarrhea. Discomfort or irritation from the vaginal ointment was also assessed. Subjects were contacted approximately 24 h after IUD insertion and asked about side effects or other new medical concerns or events during the postprocedure interval.</desc>
      <group_list>
        <group group_id="E1">
          <title>Active Nitroglycerin Ointment</title>
          <description>Insertion of nitroglycerin ointment: Nitroglycerin ointment inserted into the vagina 30-45 minutes prior to IUD insertion</description>
        </group>
        <group group_id="E2">
          <title>Placebo Ointment</title>
          <description>Insertion of placebo ointment: Placebo ointment inserted into the vagina 30-45 minutes prior to IUD insertion</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Elizabeth Micks</name_or_title>
      <organization>University of Washington</organization>
      <phone>206-616-4939</phone>
      <email>emicks@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

